861102-84-3Relevant academic research and scientific papers
Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists
Xin, Zhili,Serby, Michael D.,Zhao, Hongyu,Kosogof, Christi,Szczepankiewicz, Bruce G.,Liu, Mei,Liu, Bo,Hutchins, Charles W.,Sarris, Kathy A.,Hoff, Ethan D.,Falls, H. Douglas,Lin, Chun W.,Ogiela, Christopher A.,Collins, Christine A.,Brune, Michael E.,Bush, Eugene N.,Droz, Brian A.,Fey, Thomas A.,Knourek-Segel, Victoria E.,Shapiro, Robin,Jacobson, Peer B.,Beno, David W. A.,Turner, Teresa M.,Sham, Hing L.,Liu, Gang
, p. 4459 - 4469 (2007/10/03)
The discovery and pharmacological evaluation of potent, selective, and orally bioavailable growth hormone secretagogue receptor (GHS-R) antagonists are reported. Previously, 2,4-diaminopyrimidine-based GHS-R antagonists reported from our laboratories have
Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
-
Page/Page column 53-54, (2010/02/13)
The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.
